U.S. patent application number 10/243190 was filed with the patent office on 2003-02-27 for genetic alterations associated with prostate cancer.
This patent application is currently assigned to The Regents of the University of California. Invention is credited to Cher, Michael L., Jensen, Ronald H..
Application Number | 20030040005 10/243190 |
Document ID | / |
Family ID | 24635838 |
Filed Date | 2003-02-27 |
United States Patent
Application |
20030040005 |
Kind Code |
A1 |
Jensen, Ronald H. ; et
al. |
February 27, 2003 |
Genetic alterations associated with prostate cancer
Abstract
The present invention provides new probes for the detection of
prostate cancer cells. The probes bind selectively with target
polynucleotide sequences selected from the group consisting of 2q,
4q, 5q, 6q, 10p, 15q, 1q, 2p, 3q, 3p, 4q, 6p, 7p, 7q, 9q, 11p, 16p,
and 17q. PATENT
Inventors: |
Jensen, Ronald H.;
(Livermore, CA) ; Cher, Michael L.; (Huntington
Woods, MI) |
Correspondence
Address: |
TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO
CA
94111-3834
US
|
Assignee: |
The Regents of the University of
California
Oakland
CA
|
Family ID: |
24635838 |
Appl. No.: |
10/243190 |
Filed: |
September 12, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10243190 |
Sep 12, 2002 |
|
|
|
09294535 |
Apr 19, 1999 |
|
|
|
6451529 |
|
|
|
|
09294535 |
Apr 19, 1999 |
|
|
|
08657105 |
Jun 3, 1996 |
|
|
|
5925519 |
|
|
|
|
Current U.S.
Class: |
435/6.12 |
Current CPC
Class: |
C12Q 1/6841 20130101;
C12Q 1/6886 20130101; C12Q 1/6827 20130101; C12Q 2600/156
20130101 |
Class at
Publication: |
435/6 |
International
Class: |
C12Q 001/68 |
Claims
What is claimed is:
1. A method of screening for the presence of prostate cancer cells
in a sample, the method comprising: contacting a nucleic acid
sample from a human patient with a probe which binds selectively to
a target polynucleotide sequence on a chromosomal region which is
deleted in prostate cells and is selected from the group consisting
of 2q, 4q, 5q, 6q, 10p, and 15q, wherein the probe is contacted
with the sample under conditions in which the probe binds
selectively with the target polynucleotide sequence to form a
stable hybridization complex; and detecting the formation of a
hybridization complex.
2. The method of claim 1, wherein the nucleic acid sample is from a
prostate biopsy sample from the patient.
3. The method of claim 1, further comprising contacting the sample
with a reference probe which binds selectively to a centromeric
DNA.
4. The method of claim 1, wherein the step of detecting the
hybridization complex comprises determining the copy number of the
target sequence.
5. The method of claim 1, wherein the probe is labeled with
digoxigenin or biotin.
6. The method of claim 1, wherein the step of detecting the
hybridization complex. is carried out by detecting a fluorescent
label.
7. The method of claim 6, wherein the fluorescent label is
FITC.
8. The method of claim 1, wherein the sample comprises a metaphase
cell.
9. A method of screening for the presence of prostate cancer cells
in a sample, the method comprising: contacting a nucleic acid
sample from a human patient with a probe which binds selectively to
a target polynucleotide sequence on a genomic region in which copy
number is increased in prostate cells and is selected from the
group consisting of 1q, 2p, 3q, 3p, 4q, 6p, 7p, 7q, 9q, 11p, 16p,
and 17q, wherein the probe is contacted with the sample under
conditions in which the probe binds selectively with the target
polynucleotide sequence to form a stable hybridization complex; and
detecting the formation of a hybridization complex.
10. The method of claim 9, wherein the nucleic acid sample is from
a prostate biopsy sample from the patient.
11. The method of claim 9, further comprising contacting the sample
with a reference probe which binds selectively to a centromeric
DNA.
12. The method of claim 9, wherein the step of detecting the
hybridization complex comprises determining the copy number of the
target sequence.
13. The method of claim 9, wherein the probe is labeled with
digoxigenin or biotin.
14. The method of claim 9, wherein the step of detecting the
hybridization complex is carried out by detecting a fluorescent
label.
15. The method of claim 14, wherein the fluorescent label is
FITC.
16. The method of claim 9, wherein the sample comprises a metaphase
cell.
17. A kit for the detection of a chromosome abnormality correlated
with prostate cancer, the kit comprising a compartment which
contains a nucleic acid probe which binds selectively to a target
polynucleotide sequence in a region of a chromosome correlated with
prostate cancer, wherein the probe binds selectively with the
target polynucleotide sequence selected from the group consisting
of 2q, 4q, 5q, 6q, 10p, 15q, 1q, 2p, 3q, 3p, 4q, 6p, 7p, 7q, 9q,
11p, 16p, and 17q.
18. The kit of claim 17, wherein the probe is labeled.
19. The kit of claim 18, wherein label is selected from the group
consisting of digoxigenin and biotin.
Description
FIELD OF THE INVENTION
[0001] This invention relates to the field of cytogenetics. In
particular it provides new diagnostic nucleic acid markers for
prostate cancer.
BACKGROUND OF THE INVENTION
[0002] Molecular genetic mechanisms responsible for the development
and progression of prostate cancer remain largely unknown.
Identification of sites of frequent and recurring allelic deletion
or gain is a first step toward identifying some of the important
genes involved in the malignant process. Previous studies in
retinoblastoma (Friend, et al. Nature, 323:643-6 (1986)) and other
cancers (Cawthon, et al., Cell, 62:193-201 (1990); Baker, et al.,
Science, 244:217-21 (1989); Shuin, et al., Cancer Res, 54:2832-5
(1994)) have amply demonstrated that definition of regional
chromosomal deletions occurring in the genomes of human tumors can
serve as useful diagnostic markers for disease and are an important
initial step towards identification of critical genes. Similarly,
regions of common chromosomal gain have been associated with
amplification of specific genes (Visakorpi, et al., Nature
Genetics, 9:401-6 (1995)). Additionally, definition of the full
spectrum of common allelic changes in prostate cancer may lead to
the association of specific changes with clinical outcome, as
indicated by recent studies in colon cancer and Wilms' tumor (Jen,
et al., N. Engl. J. Med., 331:213-21 (1994); Grundy, et al., Cancer
Res, 54:2331-3 (1994)).
[0003] Prostate cancer allelotyping studies (Carter, et al., Proc
Natl Acad Sci USA, 87:8751-5 (1990); Kunimi, et al., Genomics,
11:530-6 (1991)) designed to investigate one or two loci on many
chromosomal arms have revealed frequent loss of heterozygosity
(LOH) on chromosomes 8p (50%), 10p (55%), 10q (30%), 16q (31-60%)
and 18q (17-43%). Recently, several groups have performed more
detailed deletion mapping studies in some of these regions. On 8p,
the high frequency of allelic loss has been confirmed, and the
regions of common deletion have been narrowed (Bova, et al., Cancer
Res, 53:3869-73 (1993); MacGrogan, et al., Genes Chromosom Cancer,
10:151-159 (1994); Bergerheim, et al., Genes Chromosom Cancer,
3:215-20 (1991); Chang, et al., Am T Pathol, 144:1-6 (1994);
Trapman, et al., Cancer Res, 54:6061-4 (1994); Suzuki, et al.,
Genes Chromosom Cancer, 13:168-74 (1995)). Similar efforts also
served to narrow the region of common deletion on chromosome 16q
(Bergerheim, et al., Genes Chromosom Cancer, 3:215-20 (1991); Cher,
et al., J Urol, 153:249-54 (1995)). Other prostate cancer
allelotyping studies utilizing a smaller number of polymorphic
markers have not revealed new areas of interest (Phillips, et al.,
Br J Urol, 73:390-5 (1994); Sake, et al., Cancer Res, 54:3273-7
(1994); Latil, et al., Genes Chromosom Cancer, 11:119-25 (1994);
Massenkeil, et al., Anticancer Res, 14:2785-90 (1994)). At present,
allelotyping studies are limited by the low number of loci studied,
low case numbers, heterogeneous groups of patients, the use of
tumors of low or unclear purity, and lack of standardization of
experimental techniques. For these reasons, it has been difficult
to compare frequencies of alterations between studies, and we have
yet to gain an overall view of regional chromosomal alterations
occurring in this disease.
[0004] Comparative genomic hybridization (CGH) is a relatively new
molecular technique used to screen DNA from tumors for regional
chromosomal alterations (Kallioniemi, et al., Science, 258:818-21
(1992) and WO 93/18186). Unlike microsatellite or Southern analysis
allelotyping studies, which typically sample far less than 0.1% of
the total genome, a significant advantage of CGH is that all
chromosome arms are scanned for losses and gains. Moreover, because
CGH does not rely on naturally occurring polymorphisms, all regions
are informative, whereas polymorphism-based techniques are limited
by homozygous (uninformative) alleles among a fraction of tumors
studied at every locus.
[0005] CGH can detect and map single copy losses and gains in
prostate cancer with a high degree of accuracy when compared with
the standard techniques of allelotyping (Cher, et al., Genes
Chromosom Cancer, 11:153-162 (1994)). Copy-number karyotype maps
have been generated for prostate cancer showing several recurrently
altered regions of the genome (Cher, et al., Genes Chromosom
Cancer, 11: 153-162 (1994); Visakorpi, et al., Cancer Res,
55:342-347 (1995)).
[0006] Although previous studies have begun to reveal a genome-wide
view of chromosomal alterations occurring in primary and recurrent
prostate cancer, metastatic prostate cancer has not been examined
in depth. The present invention addresses these and other needs in
the prior art.
SUMMARY OF THE INVENTION
[0007] The present invention provides compositions and methods of
detecting a genetic alterations correlated with prostate cancer.
The methods comprise contacting a nucleic acid sample from a
patient with a probe which binds selectively to a target
polynucleotide sequence correlated with prostate cancer. The
invention provides the following chromosomal regions which are
deleted in prostate cancer cells: 2q, 4q, 5q, 6q, 10p, and 15q.
Regions which show increases in copy number in prostate cancer
cells are: 1q, 2p, 3q, 3p, 4q, 6p, 7p, 7q, 9q, 11p, 16p, and
17q.
[0008] The probes of the invention are contacted with the sample
under conditions in which the probe binds selectively with the
target polynucleotide sequence to form a hybridization complex. The
formation of the hybridization complex is then detected.
[0009] Alternatively, sample DNA from the patient can be
fluorescently labeled and competitively hybridized against
fluorescently labeled normal DNA to normal lymphocyte metaphases.
Alterations in DNA copy number in the sample DNA are then detected
as increases or decreases in sample DNA as compared to normal
DNA.
[0010] The chromosome abnormality is typically a deletion or an
increase in copy number. The methods can be used to detect both
metastatic prostate cancers and in androgen independent prostate
cancer.
[0011] Definitions
[0012] A "nucleic acid sample" as used herein refers to a sample
comprising DNA in a form suitable for hybridization to a probes of
the invention. For instance, the nucleic acid sample can be a
tissue or cell sample prepared for standard in situ hybridization
methods described below. The sample is prepared such that
individual chromosomes remain substantially intact and typically
comprises metaphase spreads or interphase nuclei prepared according
to standard techniques.
[0013] The sample may also be isolated nucleic acids immobilized on
a solid surface (e.g., nitrocellulose) for use in Southern or dot
blot hybridizations and the like. In some cases, the nucleic acids
may be amplified using standard techniques such as PCR, prior to
the hybridization. The sample is typically taken from a patient
suspected of having a prostate cancer associated with the
abnormality being detected.
[0014] "Nucleic acid" refers to a deoxyribonucleotide or
ribonucleotide polymer in either single- or double-stranded form,
and unless otherwise limited, would encompass known analogs of
natural nucleotides that can function in a similar manner as
naturally occurring nucleotides.
[0015] "Subsequence" refers to a sequence of nucleic acids that
comprise a part of a longer sequence of nucleic acids.
[0016] A "probe" or a "nucleic acid probe", as used herein, is
defined to be a collection of one or more nucleic acid fragments
whose hybridization to a target can be detected. The probe is
labeled as described below so that its binding to the target can be
detected. The probe is produced from a source of nucleic acids from
one or more particular (preselected) portions of the genome, for
example one or more clones, an isolated whole chromosome or
chromosome fragment, or a collection of polymerase chain reaction
(PCR) amplification products. The probes of the present invention
are produced from nucleic acids found in the regions of genetic
alteration as described herein. The probe may be processed in some
manner, for example, by blocking or removal of repetitive nucleic
acids or enrichment with unique nucleic acids. Thus the word
"probe" may be used herein to refer not only to the detectable
nucleic acids, but to the detectable nucleic acids in the form in
which they are applied to the target, for example, with the
blocking nucleic acids, etc. The blocking nucleic acid may also be
referred to separately. What "probe" refers to specifically is
clear from the context in which the word is used.
[0017] "Hybridizing" refers the binding of two single stranded
nucleic acids via complementary base pairing.
[0018] "Bind(s) substantially" or "binds specifically" or "binds
selectively" or "hybridizing specifically to" refers to
complementary hybridization between a probe and a target sequence
and embraces minor mismatches that can be accommodated by reducing
the stringency of the hybridization media to achieve the desired
detection of the target polynucleotide sequence. These terms also
refer to the binding, duplexing, or hybridizing of a molecule only
to a particular nucleotide sequence tinder stringent conditions
when that sequence is present in a complex mixture (e.g., total
cellular) DNA or RNA. The term "stringent conditions" refers to
conditions under which a probe will hybridize to its target
subsequence, but to no other sequences. Stringent conditions are
sequence-dependent and will be different in different
circumstances. Longer sequences hybridize specifically at higher
temperatures. Generally, stringent conditions are selected to be
about 5.degree. C. lower than the thermal melting point (Tm) for
the specific sequence at a defined ionic strength and pH. The Tm is
the temperature (under defined ionic strength, pH, and nucleic acid
concentration) at which 50% of the probes complementary to the
target sequence hybridize to the target sequence at equilibrium.
Typically, stringent conditions will be those in which the salt
concentration is at least about 0.02 Na ion concentration (or other
salts) at pH 7.0 to 8.3 and the temperature is at least about
60.degree. C. Stringent conditions may also be achieved with the
addition of destabilizing agents such as formamide.
[0019] One of skill will recognize that the precise sequence of the
particular probes described herein can be modified to a certain
degree to produce probes that are "substantially identical" to the
disclosed probes, but retain the ability to bind substantially to
the target sequences. Such modifications are specifically covered
by reference to the individual probes herein. The term "substantial
identity" of polynucleotide sequences means that a polynucleotide
comprises a sequence that has at least 90% sequence identity, more
preferably at least 95%, compared to a reference sequence using the
methods described below using standard parameters.
[0020] Two nucleic acid sequences are said to be "identical" if the
sequence of nucleotides in the two sequences is the same when
aligned for maximum correspondence as described below. The term
"complementary to" is used herein to mean that the complementary
sequence is identical to all or a portion of a reference
polynucleotide sequence.
[0021] Sequence comparisons between two (or more) polynucleotides
are typically performed by comparing sequences of the two sequences
over a "comparison window" to identify and compare local regions of
sequence similarity. A "comparison window", as used herein, refers
to a segment of at least about 20 contiguous positions, usually
about 50 to about 200, more usually about 100 to about 150 in which
a sequence may be compared to a reference sequence of the same
number of contiguous positions after the two sequences are
optimally aligned.
[0022] Optimal alignment of sequences for comparison may be
conducted by the local homology algorithm of Smith and Waterman
Adv. Appl. Math. 2: 482 (1981), by the homology alignment algorithm
of Needleman and Wunsch J. Mol. Biol. 48:443 (1970), by the search
for similarity method of Pearson and Lipman Proc. Natl. Acad. Sci.
(U.S.A.) 85: 2444 (1988), by computerized implementations of these
algorithms.
[0023] "Percentage of sequence identity" is determined by comparing
two optimally aligned sequences over a comparison window, wherein
the portion of the polynucleotide sequence in the comparison window
may comprise additions or deletions (i.e., gaps) as compared to the
reference sequence (which does not comprise additions or deletions)
for optimal alignment of the two sequences. The percentage is
calculated by determining the number of positions at which the
identical nucleic acid base or amino acid residue occurs in both
sequences to yield the number of matched positions, dividing the
number of matched positions by the total number of positions in the
window of comparison and multiplying the result by 100 to yield the
percentage of sequence identity.
[0024] Another indication that nucleotide sequences are
substantially identical is if two molecules hybridize to the same
sequence under stringent conditions. Stringent conditions are
sequence dependent and will be different in different
circumstances. Generally, stringent conditions are selected to be
about 5.degree. C. lower than the thermal melting point (T.sub.m)
for the specific sequence at a defined ionic strength and pH. The
Tm is the temperature (under defined ionic strength and pH) at
which 50% of the target sequence hybridizes to a perfectly matched
probe. Typically, stringent conditions will be those as described
above.
BRIEF DESCRIPTION OF THE DRAWINGS
[0025] FIG. 1 is a graph illustrating the setting of the
t-threshold based on control, normal/normal hybridizations. For 5
control hybridizations, each with 1247 t values extending along the
genome from 1pter to Yqter (a total of 6235 t values), the y axis
gives percentage of t values with absolute value greater than the
given threshold on the x axis.
[0026] FIG. 2 is a bar graph showing percentage of the genome with
alterations. The percentage of the genome gained (shaded) and lost
(solid) is shown for each tumor specimen.
[0027] FIG. 3 is a graph showing comparison of two CGH analyses on
a single DNA specimen. One tumor DNA specimen was analyzed by CGH
analysis two times in a blinded fashion. The entire CGH procedure,
including labeling, hybridization, and analysis was performed
independently for each specimen. Each line shows t values for the
55 data channels of chromosome 10 for a single run. Threshold of
1.6 is shown by dotted lines. X-axis shows data channel number (of
1247 total) and heavy line represents region of centromere.
[0028] FIG. 4 is ideogram showing correlation of CGH and
allelotyping data. Data from two representative tumors (#50 and
#344) are depicted. Microsatellite and restriction fragment length
polymorphism analysis at 9 separate loci on chromosome 13q was
used. Mapped locations of each polymorphism (listed by D13S number)
are indicated by the dashed lines leading to the ideogram. The CGH
interpretation for each tumor is shown by the shaded bar indicating
the length and position of losses in each tumor with respect to the
ideogram. Allelotyping results are depicted as: open
circles=retained; closed circles=lost; U=uninformative. The
calculated t-statistics are shown as continuous tracings for both
tumors. The X axis is drawn at t=-1.6, and the vertical lines
connecting the tracings to the ideogram indicate the termini of the
chromosome 13q losses found in these two tumors.
[0029] FIG. 5 shows the relative frequency histograms of genetic
alterations in DNA from Group I specimens. The relative frequency
of gains and losses is shown as a region-specific histogram along
each chromosome arm. The y-axis shows the proportion of specimens
(of the 20 metastases analyzed) with t>1.6 above the central
axis and with t<-1.6 below the central axis. Centromeres and
heterochromatic regions were excluded from analysis. Histograms are
matched to ideograms of each chromosome based on the data channels
which contain the appropriate data distributed along the length of
each chromosome. Chromosome identification numbers appear in the
tipper left of each panel.
[0030] FIG. 6 shows frequency histograms of chromosomal alterations
in Group II specimens. Examples of frequency histograms for the two
chromosomes most frequently altered in Group II specimens are shown
for comparison to Group I (see FIG. 5). The frequency of gains and
losses are depicted as described in FIG. 5.
[0031] FIGS. 7A and 7B are bar graphs showing a comparison of
frequency of alterations of most frequently altered regions for the
entire set (open bars); Group I (solid bars); and Group II (shaded
bars) specimens. FIG. 7A) Gains. FIG. 7B) Losses.
DESCRIPTION OF THE PREFERRED EMBODIMENT
[0032] The present invention is based on a comprehensive molecular
cytogenetic analysis of the genomes of prostate cancer cells using
comparative genomic hybridization (CGH). In particular, a new
quantitative statistical method of CGH to identify several novel
regions of frequent deletion or gain of DNA copy numbers in
prostate cancer is provided. The results provided here also help to
clarify the relative importance of several other previously
reported regions of loss or gain. Modified function of genes
contained within the most frequently altered regions may be largely
responsible for the malignant behavior of prostate cancer.
[0033] Genetic Alterations Associated with Prostate Cancer
[0034] Genomic regions that are found to be sites of increased DNA
copy number in a large fraction of the cell lines are likely to
include oncogenes that are present at increased copy number and
hence overexpressed. Overexpression of these genes may lead to
uncontrolled growth. Regions that frequently show a decreased DNA
copy number may contain tumor suppressor genes that through
mutation of one allele and deletion on the other lead to loss of
growth or organizational control (Weinberg, Science 254:1138-1146
(1992)). Of course, some of the DNA copy number abnormalities may
arise as secondary consequences of general genomic instability
resulting from the early stages of tumorigenesis. Such alterations
are expected to occur randomly and, therefore, are not likely to be
found in a high percentage of tumors and cell lines.
[0035] In the examples described below, tumors from a set of 31
advanced prostate cancers were used to define genetic alterations
involved in both initiation and progression of prostate cancer. CGH
analysis was also corroborated with parallel Southern and
microsatellite analysis of allelic imbalance on the same DNA. The
good agreement between these two analytical techniques provides
assurance that the new, standardized CGH analysis is demonstrating
high sensitivity and specificity.
[0036] In the examples described below, multiple CGH analyses were
obtained for each chromosome in each tumor, and a point by point
comparison of the mean tumor/normal color ratio to a control
normal/normal color ratio in each of 1247 evenly distributed data
channels comprising the entire human genome was interpreted as
loss, gain, or no change in copy number in the tumor genome.
[0037] Group I tissue was obtained from prostate cancer metastases
from 20 patients, 19 of whom had received no prior prostate cancer
treatment. These samples, which contained highly enriched tumor
DNA, showed the high rates of alteration in several chromosomal
regions known to be frequently altered in prostate cancer: 8q gain
(85%), 8p loss (80%), 13q loss (75%), 16q loss (55%), 17p loss
(50%) and 10q loss (50%).
[0038] Group II tissue was obtained from 11 patients who had been
treated with long term androgen deprivation therapy and developed
androgen independent metastatic disease. Quantitative CGH analysis
on DNA from these tissues showed chromosomal alterations which were
very similar to those found in Group I, suggesting that untreated
metastatic tumors contain the bulk of chromosomal alterations
necessary for recurrence to occur during androgen deprivation.
[0039] In the entire data set, a number of previously undetected
regions of frequent loss or gain were identified, including losses
of chromosomes 2q (42%), 5q (39%), 6q (39%), and 15q (39%) and
gains of chromosomes 11p (52%), 1q (52%), 3q (52%), and 2p
(45%).
[0040] A summary of these results is provided in FIG. 7. As used
here, a "region" is at least 5 contiguous channels. A particular
abnormality is considered to occur "frequently" if it occurs in
greater than 20% of the tumors tested.
[0041] Regions of Loss.
[0042] These regions are suspected to carry at least one recessive
oncogene; in fact, many of the most frequently lost regions contain
known or candidate tumor suppressor genes. For example the most
intensively studied tumor suppressor gene, p53, is located on 17p
and previously was shown to be mutated in 20-25% of metastatic
prostate cancers (Bookstein, et al., Cancer Res, 53:3369-73
(1993)). It also has been reported as mutated in {fraction (8/16)}
(50%) prostate cancer bone marrow metastases (Aprikian, et al., J.
Urol, 151:1276-80 (1994)) and was shown to suppress in vitro growth
of prostate cancer cell lines (Isaacs, et al., Cancer Res,
51:4716-20 (1991)). Loss of 17p was detected in 50% of Group I
tumors as compared with 65% of Group II tumors. These data taken
together support the view that loss of normal p53 function is
associated with prostate tumor progression, and it appears to be an
alteration which occurs most commonly in late stages of the
disease.
[0043] Chromosome 10q22.1-qter contains the candidate tumor
suppressor gene Mxi1, previously reported to be mutated in four
prostate cancer cases (Eagle, et al., Nature Genetics, 9:249-255
(1995)). Since the Mxi1 protein is suspected to repress c-Myc
activity (Zervos, et al., Cell, 72:223-32 (1993)), loss of Mxi1
activity may lead to activation of c-Myc. In concert with potential
increased chromosome 8q copy number (discussed below), increased
c-Myc activity may be a common theme in prostate cancer.
[0044] Chromosome 5q contains the alpha catenin gene (5q31)
(Furukawa, et al., Cytogen Cell Genet, 65:74-8 (1994)), which is a
necessary component of the E-cadherin mediated cell adhesion
complex. It has previously been shown that five of the six human
prostate cancer cell lines have reduced or absent levels of alpha
catenin or E-cadherin as compared with normal prostatic epithelial
cells (Morton, et al., Cancer Res, 53:3585-90 (1993)).
[0045] Two other frequently lost regions containing known candidate
tumor suppressor genes are chromosome 13q (contains Rb1) and 16q
(contains E-cadherin). Interestingly, close analysis of the
patterns of loss on these chromosomal arms suggests that more than
one important prostate cancer tumor suppressor gene may be located
on 13q and 16q. Although the frequency of loss for all 31 tumors
studied increases from 40% to 60% across 13q14, where Rb1 is
located, the peak appears just distal to 13q14 and is sustained
near 60% across 13q21. 1-q31 (see FIGS. 5 and 6). While previous
studies have shown that loss of Rb1 expression (Bookstein, et al.,
Proc Natl Acad Sci USA, 87:7762-6 (1990)) and allelic loss of this
gene (Brooks, et al., Prostate, 26:35-9 (1995)) do occur in
prostate tumors, the CGH findings raise the possibility that there
is a second important prostate cancer tumor suppressor gene on
chromosome 13q distal to Rb1. Similarly, while decreased E-cadherin
expression is associated with poor prognosis in prostate cancer
(Umbas, et al., Cancer Res, 54:3929-33 (1994); Umbas, et al.,
Cancer Res, 52:5104-9 (1992)), and 30% of all 31 tumors in this
study show loss in this region; there is a separate region of 40%
loss at 16q24 that may signify the site of another important
prostate cancer tumor suppressor gene. This regional mapping is in
agreement with a previous cosmid deletion mapping study on 16q
(Cher, et al., J Urol, 153:249-54 (1995)).
[0046] The other regions of frequent loss do not possess genes that
previously have been identified as candidate tumor suppressor
genes. However, the fact that these regions are lost at high
frequency in advanced tumors indicates that they detection of these
regions is useful in diagnostic and prognostic applications. The
evidence also strongly indicates that genes of importance to the
progression of this disease may exist at these sites. In
particular, there is great interest in the frequent loss of
chromosome 8p, and a number of research groups are investigating
this region for the presence of an important tumor suppressor gene
(Bova, et al., Cancer Res, 53:3869-73 (1993); MacGrogan, et al.,
Genes Chromosom Cancer, 10:151-159 (1994); Chang, et al., Am T
Pathol, 144:1-6 (1994); Trapman, et al., Cancer Res, 54:6061-4
(1994); Cher, et al., Genes Chromosom Cancer, 11:153-162 (1994);
Matsuyama, et al., Oncogene, 9:3071-3076 (1994)). Regions 2q, 6q,
10p and 15q also fall into this category. These regions are
therefore useful as genetic markers and should be analyzed more
extensively for tumor suppressor genes.
[0047] Regions of Gain.
[0048] In these regions, dominant oncogenes that exhibit increased
expression with increased copy number are expected to be found. The
most notable of these is chromosome 8q, where the c-Myc oncogene is
located. Amplification of this region has previously been shown to
be correlated with adverse prognosis in prostate cancer (Van Den
Berg, et al., Clin Ca Res, 1:11-18 (1993)). The frequency of gain
of 8q detected by CGH is much higher than reported previously in
smaller series (Bova, et al., Cancer Res, 53:3869-73 (1993); Van
Den Berg, et al., Clin Ca Res, 1:11-18 (1993)) and may--reflect the
superior ability to detect gain using CGH.
[0049] Chromosome 11p shows gains in 52% of the specimens in the
data presented below, and the potent oncogene H-Ras is located at
11p15.5. While this region is not identified as the most common
region of gain (11p13-p15.3), CGH is unreliable near telomeres due
to fluorescence intensity losses at the termini. Thus, it may be
that this oncogene is included in a region frequently gained in
advanced prostate cancer. Notably it was determined that 40%
({fraction (8/20)}) of the metastases show gains at 11p15.5 (see
FIG. 5). While it is possible that this gain in copy number could
be responsible for H-Ras activation in prostate cancer, mutation or
promoter induction could also induce activation, although previous
studies have shown only 3H-Ras gene mutations in 94 samples
analyzed (Isaacs, et al., Sem Oncol., 21;514-21 (1994)).
[0050] Another region which contains a known oncogene is chromosome
7p, where erbB-1 (=EGFR) is located. Although it has been shown
that trisomy in chromosome 7 is associated with higher grade and
stage of prostate cancer (Bandyk, et al., Genes Chromosom Cancer,
9:19-27 (1994); Stephenson, et al., Cancer Res, 47:2504-7 (1987)),
no strong evidence has been published which indicates specific
gene(s) on this chromosome that are important to the phenotype.
[0051] FIG. 7 shows that chromosome 7q displays gains in up to 40%
of the specimens from both the metastases and the androgen
independent tumors. Recently, it has been shown that the c-met
oncogene, which maps to 7q31, is expressed in the basal epithelial
cells of 36/43 primary prostate cancer samples, 4/4 lymph node
metastases and 23/23 bone marrow metastases (Pisters, et al.,
Journal of Urology, 154:293-8 (1995)).
[0052] FIG. 7 indicates that gains occur at a frequency of 0.39 in
a region of chromosome 17q that includes BRCA1, while Gao et al.
recently showed frequent PCR-based LOH of BRCA1 on chromosome 17q
in prostate cancer (Gao, et al., Cancer Res, 55:1002-5 (1995)).
Again, these results could be explained by somatic recombination
followed by gain, or incorrect interpretation of PCR allelic
bands.
[0053] The oncogene erbB-2 is located at 17q12, which is in the
vicinity of the region of high frequency of gain by CGH. Previously
Kuhn et al. have shown that 18/53 clinically localized prostate
cancers expressed high levels of this gene with no indications of
high level gene amplification (Kuhn, et al. Journal of Urology
(1993)). It is possible that the modest increase in copy number
that is evident in the present analyses is responsible for such
increased gene expression.
[0054] The androgen receptor gene, located in Xq12, was shown
previously to display gains at a relatively high frequency
({fraction (4/9)}) in recurrent prostate tumors (Visakorpi, et al.,
Cancer Res, 55:342-347 (1995)). In a subsequent report, Visakorpi
et al. showed that amplification of Xq12 is associated with tumor
recurrence in individuals during androgen deprivation therapy
(Visakorpi, et al., Nature Genetics, 9:401-6 (1995)). Although this
region was gained in only {fraction (5/31)} (16%) of the entire
group of tumors studied here it was gained in {fraction (3/11)}
(27%) of the Group II androgen independent tumors. Thus, the
present studies are in general agreement with those of Visakorpi et
al. and support their suggestion that tumor cells with androgen
receptor amplification are selected during androgen deprivation
therapy. However, amplification of this region is not restricted to
tumors failing hormonal therapy.
[0055] African Americans.
[0056] The results presented below show increased frequency of
gains in the region 4q25-q28 in African Americans (p<0.001). A
gene could be located on 4q which is more frequently increased in
activity and induces more rapid clinical progression of prostate
cancer among African-Americans (Pienta, et al., Urology, 45:93-101,
(1993); Brawn, et al., Cancer, 71:2369-73 (1993)).
[0057] Detecting Genetic Alterations
[0058] Using the results provided here, one of skill can prepare
nucleic acid probes specific to particular genomic regions of
genetic alteration that are associated with prostate cancer. The
probes can be used in a variety of nucleic acid hybridization
assays to detect the presence (in particular increased copy number)
or absence of the regions for the early diagnosis or prognosis of
cancer. As noted above, the probes are primarily useful for the
diagnosis or prognosis of prostate cancer. The regions can also be
used for a large number of other cancers. These include, but are
not limited to breast, ovary, bladder, head and neck, and
colon.
[0059] The genetic alterations are detected through the
hybridization of a probe of this invention to a nucleic acid sample
in which it is desired to screen for the alteration. Suitable
hybridization formats are well known to those of skill in the art
and include, but are not limited to, variations of Southern Blots,
in situ hybridization and quantitative amplification methods such
as quantitative PCR (see, e.g. Sambrook, Molecular Cloning--A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring
Harbor, N.Y., (1989), Kallioniemi et al., Proc. Natl Acad Sci USA,
89: 5321-5325 (1992), and PCR Protocols, A Guide to Methods and
Applications, Innis et al., Academic Press, Inc. N.Y., (1990)).
[0060] In situ Hybridization.
[0061] In a preferred embodiment, the regions disclosed here are
identified using in situ hybridization. Generally, in situ
hybridization comprises the following major steps: (1) fixation of
tissue or biological stricture to analyzed; (2) prehybridization
treatment of the biological structure to increase accessibility of
target DNA, and to reduce nonspecific binding; (3) hybridization of
the mixture of nucleic acids to the nucleic acid in the biological
structure or tissue; (4) posthybridization washes to remove nucleic
acid fragments not bound in the hybridization and (5) detection of
the hybridized nucleic acid fragments. The reagent used in each of
these steps and their conditions for use vary depending on the
particular application.
[0062] In some applications it is necessary to block the
hybridization capacity of repetitive sequences. In this case, human
genomic DNA is used as an agent to block such hybridization. The
preferred size range is from about 200 bp to about 1000 bases, more
preferably between about 400 to about 800 bp for double stranded,
nick translated nucleic acids.
[0063] Hybridization protocols for the particular applications
disclosed here are described in Pinkel et al. Proc. Natl. Acad.
Sci. USA, 85: 9138-9142 (1988) and in EPO Pub. No. 430,402.
Suitable hybridization protocols can also be found in Methods
o.backslash.in Molecular Biology Vol. 33: In Situ Hybridization
Protocols, K. H. A. Choo, ed., Humana Press, Totowa, N.J., (1994).
In a particularly preferred embodiment, the hybridization protocol
of Kallioniemi et al., Proc. Natl Acad Sci USA, 89: 5321-5325
(1992) is used.
[0064] Typically, it is desirable to use dual color FISH, in which
two probes are utilized, each labelled by a different fluorescent
dye. A test probe that hybridizes to the region of interest is
labelled with one dye, and a control probe that hybridizes to a
different region is labelled with a second dye. A nucleic acid that
hybridizes to a stable portion of the chromosome of interest, such
as the centromere region, is often most useful as the control
probe. In this way, differences between efficiency of hybridization
from sample to sample can be accounted for.
[0065] The FISH methods for detecting chromosomal abnormalities can
be performed on nanogram quantities of the subject nucleic acids.
Paraffin embedded tumor sections can be used, as can fresh or
frozen material. Because FISH can be applied to the limited
material, touch preparations prepared from uncultured primary
tumors can also be used (see, e.g., Kallioniemi, A. et al.,
Cytogenet. Cell Genet. 60: 190-193 (1992)). For instance, small
biopsy tissue samples from tumors can be used for touch
preparations (see, e.g., Kallioniemi, A. et al., Cytogenet. Cell
Genet. 60: 190-193 (1992)). Small numbers of cells obtained from
aspiration biopsy or cells in bodily fluids (e.g., blood, urine,
sputum and the like) can also be analyzed.
[0066] Southern Blots.
[0067] In a Southern Blot, a genomic or cDNA (typically fragmented
and separated on an electrophoretic gel) is hybridized to a probe
specific for the target region. Comparison of the intensity of the
hybridization signal from the probe for the target region with the
signal from a probe directed to a control (non amplified or
deleted) such as centromeric DNA, provides an estimate of the
relative copy number of the target nucleic acid. Procedures for
carrying out Southern hybridizations are well known to those of
skill in the art. see, e.g., Sambrook et al., supra.
[0068] Preparation of Probes of the Invention
[0069] A number of methods can be used to identify probes which
hybridize specifically to the regions identified here. For
instance, probes can be generated by the random selection of clones
from a chromosome specific library, and then mapped to each
chromosome or region by digital imaging microscopy. This procedure
is described in U.S. Pat. No. 5,472,842. Briefly, a selected
chromosome is isolated by flow cytometry, according to standard
procedures. The chromosome is then digested with restriction
enzymes appropriate to give DNA sequences of at least about 20 kb
and more preferably about 40 kb. Techniques of partial sequence
digestion are well known in the art. See, for example Perbal, A
Practical Guide to Molecular Cloning 2nd Ed., Wiley N.Y. (1988).
The resulting sequences are ligated with a vector and introduced
into the appropriate host. Exemplary vectors suitable for this
purpose include cosmids, yeast artificial chromosomes (YACs),
bacterial artificial chromosomes (BACs) and P1 phage. Typically,
cosmid libraries are prepared. Various libraries spanning entire
chromosomes are also available commercially (Clonetech, South San
Francisco, Calif.) or from the Los Alamos National Laboratory.
[0070] Once a probe library is constructed, a subset of the probes
is physically mapped on the selected chromosome. FISH and digital
image analysis can be used to localize clones along the desired
chromosome. Briefly, the clones are mapped by FISH to metaphase
spreads from normal cells using e.g., FITC as the fluorophore. The
chromosomes may be counterstained by a stain which stains DNA
irrespective of base composition (e.g., propidium iodide), to
define the outlining of the chromosome. The stained metaphases are
imaged in a fluorescence microscope with a polychromatic
beam-splitter to avoid color-dependent image shifts. The different
color images are acquired with a CCD camera and the digitized
images are stored in a computer. A computer program is then used to
calculate the chromosome axis, project the two (for single copy
sequences) FITC signals perpendicularly onto this axis, and
calculate the average fractional length from a defined position,
typically the p-telomere.
[0071] The accuracy of the mapped positions of the probes can be
increased using interphase mapping. Briefly, the distance between
two probes which are found by metaphase mapping to be very close is
measured in normal interphase nuclei. The genomic distance between
the two is equal to the square of the physical distance (Van den
Engh et al., Science 257:1410 (1992)). If the order is uncertain,
the probes are labeled with different colors and their relative
distance to a third (distant) probe can be reassessed. Trask et
al., Am. J. Hum. Genet. 48:1 (1991).
[0072] Typically, a mapped library will consist of between about 20
and about 125 clones, more usually between about 30 and about 50
clones. Ideally, the clones are distributed relatively uniformly
across the region of interest, usually a whole chromosome.
[0073] Sequence information of the region identified here permits
the design of highly specific hybridization probes or amplification
primers suitable for detection of the target sequences. This is
useful for diagnostic screening systems as well as research
purposes. Means for detecting specific DNA sequences are well known
to those of skill in the art. For instance, oligonucleotide probes
chosen to be complementary to a selected subsequence with the
region can be used. Alternatively, sequences or subsequences may be
amplified by a variety of DNA amplification techniques (for example
via polymerase chain reaction, ligase chain reaction, transcription
amplification, etc.) prior to detection using a probe.
Amplification of DNA increases sensitivity of the assay by
providing more copies of possible target subsequences. In addition,
by using labeled primers in the amplification process, the DNA
sequences may be labeled as they are amplified.
[0074] Labeling Probes
[0075] Methods of labeling nucleic acids are well known to those of
skill in the art. Preferred labels are those that are suitable for
use in in situ hybridization. The nucleic acid probes may be
detectably labeled prior to the hybridization reaction.
Alternatively, a detectable label which binds to the hybridization
product may be used. Such detectable labels include any material
having a detectable physical or chemical property and have been
well-developed in the field of immunoassays.
[0076] As used herein, a "label" is any composition detectable by
spectroscopic, photochemical, biochemical, immunochemical, or
chemical means. Useful labels in the present invention include
radioactive labels (e.g. .sup.32P, .sup.125I, .sup.14C, .sup.3H,
and .sup.35S), fluorescent dyes (e.g. fluorescein, rhodamine, Texas
Red, etc.), electron-dense reagents (e.g. gold), enzymes (as
commonly used in an ELISA), calorimetric labels (e.g. colloidal
gold), magnetic labels (e.g. Dynabeads.TM.), and the like. Examples
of labels which are not directly detected but are detected through
the use of directly detectable label include biotin and dioxigenin
as well as haptens and proteins for which labeled antisera or
monoclonal antibodies are available.
[0077] The particular label used is not critical to the present
invention, so long as it does not interfere with the in situ
hybridization of the stain. However, stains directly labeled with
fluorescent labels (e.g. fluorescein-12-dUTP, Texas Red-5-dUTP,
etc.) are preferred for chromosome hybridization.
[0078] A direct labeled probe, as used herein, is a probe to which
a detectable label is attached. Because the direct label is already
attached to the probe, no subsequent steps are required to
associate the probe with the detectable label. In contrast, an
indirect labeled probe is one which bears a moiety to which a
detectable label is subsequently bound, typically after the probe
is hybridized with the target nucleic acid.
[0079] In addition the label must be detectible in as low copy
number as possible thereby maximizing the sensitivity of the assay
and yet be detectible above any background signal. Finally, a label
must be chosen that provides a highly localized signal thereby
providing a high degree of spatial resolution when physically
mapping the stain against the chromosome. Particularly preferred
fluorescent labels include fluorescein-12-dUTP and Texas
Red-5-dUTP.
[0080] The labels may be coupled to the probes in a variety of
means known to those of skill in the art. In a preferred embodiment
the nucleic acid probes will be labeled using nick translation or
random primer extension (Rigby, et al. J. Mol. Biol., 113: 237
(1977) or Sambrook, et al.).
[0081] One of skill in the art will appreciate that the probes of
this invention need not be absolutely specific for the targeted
region of the genome. Rather, the probes are intended to produce
"staining contrast". "Contrast" is quantified by the ratio of the
probe intensity of the target region of the genome to that of the
other portions of the genome. For example, a DNA library produced
by cloning a particular chromosome (e.g. chromosome 7) can be used
as a stain capable of staining the entire chromosome. The library
contains both sequences found only on that chromosome, and
sequences shared with other chromosomes. Roughly half the
chromosomal DNA falls into each class. If hybridization of the
whole library were capable of saturating all of the binding sites
on the target chromosome, the target chromosome would be twice as
bright (contrast ratio of 2) as the other chromosomes since it
would contain signal from the both the specific and the shared
sequences in the stain, whereas the other chromosomes would only be
stained by the shared sequences. Thus, only a modest decrease in
hybridization of the shared sequences in the stain would
substantially enhance the contrast. Thus contaminating sequences
which only hybridize to non-targeted sequences, for example,
impurities in a library, can be tolerated in the stain to the
extent that the sequences do not reduce the staining contrast below
useful levels.
[0082] Kits Containing Probes of the Invention.
[0083] This invention also provides diagnostic kits for the
detection of chromosomal abnormalities at the regions disclosed
here. In a preferred embodiment, the kits include one or more
probes to the regions described herein. The kits can additionally
include blocking probes, instructional materials describing how to
use the kit contents in detecting the alterations. The kits may
also include one or more of the following: various labels or
labeling agents to facilitate the detection of the probes, reagents
for the hybridization including buffers, a metaphase spread, bovine
serum albumin (BSA) and other blocking agents, sampling devices
including fine needles, swabs, aspirators and the like, positive
and negative hybridization controls and so forth.
EXAMPLES
[0084] Materials and Methods
[0085] Metastatic or primary tumor tissue was obtained from two
groups of patients with metastatic prostate cancer (see Table 1).
Group I consisted of 20 patients who had not been exposed to long
term androgen deprivation or other therapies. Group II consisted of
11 patients with clinical disease progression despite long term
androgen deprivation therapy (androgen independent disease).
[0086] Group I Tissue from Metastases. Eighteen of these twenty
patients were initially thought to have tumors confined to the
prostate but were later found have pelvic lymphatic metastases at
the time of staging pelvic lymphadenectomy. Portions of the
metastatic cancer tissue obtained at lymphadenectomy were used for
this study. None of these eighteen had undergone androgen
deprivation therapy, chemotherapy, or radiation therapy prior to
this surgery. The remaining two samples were obtained from patients
with prostate cancer metastatic to the bone. One of these patients
(#375) underwent androgen deprivation therapy one month prior to
bone biopsy. The other patient (#391) received no therapy prior to
bone biopsy.
[0087] Considering these 20 patients together, the mean age at the
time of tissue sampling was 61 years, with a range of 44-72 years.
Five of the men are of African-American descent, the other 15 are
Caucasian, with no more detailed ethnic data available. Mean serum
PSA (Hybritech) one day to 20 weeks prior to pelvic node dissection
or bone biopsy for the 20 men was 61 ng/ml, with a range of 3.3-250
ng/ml. Mean prostate biopsy Gleason score (Gleason, D. F., Cancer
Chemother Rep, 50:125-8 (1966)) for the 18 men found to have pelvic
metastases was 7, with a range of 4-9 (Table 1). Family history of
prostate cancer was available for 12/20 patients, and was negative
for all 12.
[0088] Precise histological control was achieved for all tissues
studied in this group using the following protocol. Tissues not
needed for histological diagnosis were snap frozen at -80.degree.
C. within 10-30 minutes after surgical removal. Serial cryostat
sectioning was used to identify portions of the sample containing a
lower fraction of tumor cells. These areas were removed from the
tissue block by microdissection every 300 .mu.M. The area of tissue
remaining after microdissection varied from approximately 2.times.5
mm to 10.times.20 mm. The estimated tumor cell fraction (fraction
of the sample composed of tumor cells as opposed to lymphocytes or
stromal cells) was determined by visual estimation in 20 randomly
selected fields examined at total magnification of 100.times.
(Olympus Optical Co., Ltd., Japan) and averaged for all
histological sections produced during serial sectioning (Table 1).
DNA was obtained from between 200 and 1000 6.mu. sections for each
case. If we estimate that one tumor cell is contained in every
1000.mu..sup.3 tissue volume, the samples studied consisted of DNA
pooled from between 10.sup.7 and 10.sup.9 metastatic prostate
cancer cells. DNA purification was performed as described
previously (Bova, et al., Cancer Res, 53:3869-73 (1993)). Aliquots
of the same DNA samples were used for both allelotyping and CGH.
For both Southern and microsatellite analysis, noncancerous
comparison DNA was prepared from pooled blood lymphocytes from each
patient.
[0089] Group II Tissue from Androgen Independent Cases. These
patients showed clinical disease progression despite long term
androgen deprivation therapy. Four patients underwent transurethral
resection for locally advanced tumor obstructing the bladder
outlet, 6 patients underwent core biopsy of recurrent pelvic tumor
after radical prostatectomy, and one patient suffered a scrotal
skin metastasis. Thus, genetic analysis was performed on primary
tumor in 4 cases, persistent or recurrent primary tumor in 6 cases,
and metastatic tumor in one case.
[0090] Considering these 11 patients together, the mean age at the
time of tissue sampling was 72 years, with a range of 43-96 years.
All of these 11 patients are Caucasian, with no more detailed
ethnic data available. Mean serum PSA at the time of diagnosis of
metastatic prostate cancer was 272 ng/ml with a range of 14.9-1632
ng/ml. Mean Gleason Score was 7.6 with a range of 6-10.
[0091] Histological control was less precise for these tissues,
since the estimated tumor cell fraction was not determined directly
on the piece of tissue from which DNA was isolated. Instead, it was
estimated from a histological section of a nearby piece of tissue
removed during the same surgical procedure. Thus, the estimated
tumor cell fraction listed in Table 1 is less precise than for
Group I. DNA was isolated from fresh tissue brought immediately
from the operating room or clinic by proteinase K dissection and
phenol-chloroform-isoamyl alcohol extraction. Serial cryostat
sectioning was not used.
[0092] Comparative Genomic Hybridization. CGH was performed as
described previously (Cher, et al., Genes Chromosom Cancer,
11:153-162 (1994)) with the modification that DNA was labeled by
direct incorporation of fluorochrome-linked nucleotides. Briefly,
tumor DNA (0.5-1 .mu.g) was labeled by nick translation in the
presence of 20 .mu.M daTP, dCTP, dGTP and FITC-12-dUTP (NEN
Research Products, Boston, Mass.). Normal DNA, isolated from the
lymphocytes of a laboratory volunteer, was labeled in an identical
fashion using Texas Red-5-dUTP (NEN Research Products).
Hybridization with 0.2-1.0 .mu.g of labeled tumor and normal DNA
and 10 .mu.g of Cot-1 DNA was performed on metaphase spreads from a
normal donor's lymphocytes for 2-3 days, the slides were washed,
dehydrated in ethanol, and the metaphase spreads were
counter-stained with 0.1 .mu.M DAPI.
[0093] Five to 10 fluorescence microscopic metaphase images of each
color were acquired for each tumor/normal hybridization; 4 to 5
images were chosen for quantitative analysis. For each metaphase
image, green (tumor) and red (normal) fluorescence intensity values
were calculated as described previously (Cher, et al., Genes
Chromosom Cancer, 11:153-162 (1994); Kallioniemi, et al., Genes
Chromosom Cancer, 10:231-43 (1994)). The green and red fluorescence
intensity values along each chromosome were then assigned to data
channels appropriate for their location in the genome. There were
1247 data channels extending along the length of the genome from
1pter to Yqter with the number of channels for each chromosome
assigned to a fixed value based on the relative lengths of the
chromosomes (Morton, N.E., Proc Natl Acad Sci USA, 88:7474-6
(1991); Lucas, et al., Cytometry, 8:273-9 (1987)). Thus channels 1
to 100 contained fluorescence intensities measured for chromosome
1, channels 101-197 contained intensities for chromosome 2, etc.
Each metaphase image generally yielded intensity values of each
color for both members of all autosome pairs and one intensity
value of each color for chromosome X and chromosome Y. Fluorescence
intensity of each color was normalized for a given metaphase and
the ratios of green/red were calculated for each data channel for
each chromosome image. Green/red fluorescence intensity ratio
distributions (mean and standard deviation) were then calculated
for each data channel taking into account the ratios from every
chromosomal image in every metaphase that was analyzed. In general,
averages over 7 images of each autosome were combined (range 4-10)
to provide a fluorescence intensity ratio profile distribution
along the genome for each tumor.
[0094] Quantitative Analysis by CGH. In order to quantitatively
analyze CGH data, we compared results from tumor/normal
hybridizations with those from normal/normal controls. Thus, we
performed 5 two-color hybridizations involving only normal DNA
labeled both green and red to be used as controls for comparison
with tumor/normal hybridizations. CGH was performed using the same
methodology as that used for tumor DNA. For each of these control
hybridizations, 4 metaphase images were analyzed resulting in tip
to 8 images for each autosome and 4 images for each sex chromosome.
As expected, the green/red ratios were centered around 1.0 along
the length of the genome for each of these control hybridizations.
However, close examination of the ratios revealed that many genomic
regions consistently showed green/red ratios slightly different
from 1.0. For example, the region corresponding to chromosome
1p32-1pter showed an average green/red ratio of 1.07, the region
corresponding to chromosome 19 showed an average ratio of 1.08, and
the region corresponding to chromosome 4q showed an average ratio
of 0.952. The cause of these consistent deviations in the green/red
ratios in the normal/normal control hybridizations was unknown. We
suspect that hybridization properties are slightly altered by
incorporation of conjugated uridine into the probe DNA, and these
hybridization differences are revealed by slight variations in
particular regions of the metaphase chromosomes, perhaps due to
protein/DNA interactions or chromosomal structure. Additionally,
standard deviations of the ratios tended to vary from region to
region. For example, standard deviations tended to increase near
chromosomal telomeres and centromeres. At the centromeres this can
be explained by the fact that unlabeled Cot-1 DNA was added to
block non-specific repetitive DNA hybridization by the labeled
DNAs, and since large amounts of repetitive DNA is present at the
centromeres, a decreased intensity of both green and red
fluorescence resulted in these regions. The decreased intensity of
both fluorescence colors resulted in lower precision in the
intensity measurements and ratio calculations. At the telomeres
there appears to be a slight uncertainty in the definition of the
exact terminus as determined by the image analysis algorithm due to
the fact that there is a large area of local background which
causes local decrease in the chromosomal image intensity for both
colors. As with the centromeric regions, this resulted in a lower
precision in intensity measurements at the telomeres.
[0095] Data from these 5 control normal/normal hybridizations,
obtained under the same experimental conditions as for the
tumor/normal hybridizations, were combined to model the behavior of
the ratios when no genetic alterations were present. Therefore,
each of the 1247 data channels along the genome in the control
hybridizations was assigned a specific green/red fluorescence
intensity ratio distribution. We then compared the green/red
distributions for each tumor/normal hybridization to those for the
combined pool of control normal/normal hybridizations. A
t-statistic was calculated independently for each channel along the
genome to test whether the mean ratio for a tumor/normal
hybridization was significantly different from the mean ratio for
the control normal/normal hybridizations. At each of the 1247 data
channels, larger absolute values of t indicated higher statistical
confidence that a chromosomal alteration was truly present.
Positive values of t indicated gain of genetic material in the
tumor DNA while negative values of t indicated loss of genetic
material. Finally, centromeric and heterochromatic regions were
excluded from interpretation since hybridization in these regions
is imprecise (Kallioniemi, et al., Genes Chromosom Cancer,
10:231-43 (1994)).
[0096] In quantitative CGH analysis, a threshold t, value must be
chosen in order to use the t-statistic for defining whether a ratio
at any point along the genome indicates a significant gain or loss
of genetic material in any given tumor DNA sample. The value of the
threshold directly affects the sensitivity and specificity of CGH
analysis and should be set according to the goals of the study. To
define this threshold for our study, we calculated the statistics
for each of the normal/normal control hybridizations by comparing
each one to the complete set of 5 control hybridizations. During
this analysis, we found that smoothing the normal/normal ratio
variances by averaging over several contiguous channels prior to
formation of the t-statistic, greatly reduced the number of false
"gains" and "losses" in the control hybridizations. Thus, we
adopted this procedure for all our t-statistical calculations, and
the variance in each data channel for the normal/normal elements in
the analysis was averaged with those of 5 contiguous channels on
each side of that channel. Within 5 channels of chromosomal termini
and centromeres, the number of contiguous channels in this
averaging was decreased systematically by averaging only to the
terminus or centromere. Using this procedure for t-statistical
evaluation, the t values for all of the control hybridizations were
near zero with very few elevated positive or negative values (FIG.
1). For example, 99% of t values for the control hybridizations
were between -1.36 and 1.36. For this study, we chose a threshold
of .vertline.t.vertline.>1.6 for the definition of losses and
gains. At this threshold level less than 0.3% (17 out of 6235)
.vertline.t.vertline. values from the 5 normal/normal control
hybridizations were over the threshold. Based on the curve shown in
FIG. 1, lowering the t threshold would result in a rapid loss of
specificity (increase false-positives); also, this threshold level
resulted in a high level of sensitivity for the detection of
chromosomal alterations based on the high level of concordance with
the independently performed allelotyping experiments (see
Results).
[0097] Allelotyping. For the 20 Group I metastatic tumors. Southern
analysis was carried out at 29 loci on 19 chromosome arms, and
microsatellite analysis was performed at 24 loci on 7 arms. Many of
the loci were chosen because they fell within regions previously
found to be relevant to prostate cancer. In particular, we tested
multiple loci on the following chromosome arms (chromosome
arm/number of loci compared): 2q/3; 8p/9; 10q/5; 13q/12; 16q/-5;
18q/3. In addition, 12 other chromosome arms were represented with
one or two loci each.
[0098] Loci studied by Southern analysis were D1S57, D1S74, D2S44,
D2S48, D2S50, D2S53, RAF1(3p), D4S125, D6S44, D7S150, KSR (8p), MSR
(8p), D8S140, D8S220, D8S194, D8S39, IFNB1 (9p), D10S25, D10S28,
D13S1, D13S2, D16S7, CEPT-A/B (16q), TAT (16q), D17S5, D17S34,
D17S74, DCC (18q), and DYZ4 (Y). Southern analysis was performed as
described in Bova, et al., Cancer Res, 53:3869-73 (1993).
[0099] Loci studied by microsatellite analysis were D2S123, APC
(5q), D8S201, LPL (8p), D8S261, D8S264, D10S190, D10S192, D10S201,
D10S217, D13S115, D13S121, D13S134, D13S146, D13S147, D13S152,
D13S170, D13S171, D13S175, D13S309, D16S26, D16S402, D18S61, and
D18S69 (Weissenbach, et al., Nature, 359:794-801 (1992)).
Microsatellite analysis was performed as described in Bova, et al.,
supra.
[0100] Allelic loss using Southern and microsatellite analysis was
defined as the absence of one allele in prostatic tumor DNA
compared to the noncancerous paired control DNA as defined by
inspection of the autoradiograph. In some cases, when there was
residual signal from contaminating normal tissue, densitometry was
used for analysis. A sample was scored as having allelic loss if
approximately 60% reduction was present in the diminished allele
compared to its normalized retained counterpart.
[0101] Only one region (chromosome 8q) showed allelic gain by
Southern blotting. Allelic gain using probe MCT 128.2 (8q) was
defined as an increase in intensity of greater than 100% of one of
two alleles present in tumor samples, or intensity differences of
greater than 100% between tumor and normal alleles in homozygous
cases when prior probing of the same blots demonstrated equal
loading of DNA in tumor and normal lanes. Allelotyping measurements
were performed and analyzed in a blinded fashion with respect to
the CGH findings.
[0102] Results
[0103] Hybridization quality. We found that the direct labeling
technique of incorporation of fluorochrome-linked nucleotides into
genomic DNA resulted in higher quality hybridization when compared
with the older technique of detection using fluorochrome-linked
secondary reagents (Cher, et al., Genes Chromosom Cancer, 11:
153-162 (1994)). By fluorescence microscopic examination this
increase in quality could be seen as less granular images with
sharper transitions of color at the termini of losses and gains.
Additionally image analysis tracings of the fluorescence ratios
were smoother, such that when data from multiple images were
combined, the standard deviations of the fluorescence ratios were
reduced.
[0104] CGH rising t threshold 1.6. On all tumor DNA samples were
applied quantitative CGH as described in Material and Methods,
using t thresholds of +1.6 for gains and -1.6 for losses. With this
analytical approach, all tumors in both groups of specimens
displayed some DNA alterations (losses or gains relative to average
DNA copy number). The proportion of the genome with either losses
or gains was calculated for each tumor and is depicted in FIG. 2.
It is clear that a large fraction of the genome appears altered in
most specimens. Thus, the high level of specificity obtained by
using .vertline.t.vertline.>1.6 did not sacrifice the
sensitivity to detect changes. It should also be noted that the
three tumors with the least altered genomes are from group II. This
most likely reflects lower tumor cell fraction in these samples as
shown in Table 1. Samples displayed many different relative
proportions of gains and losses, with no specific pattern among
samples in each group. Overall, there were nearly equal proportions
of the genome involved in gains as in losses: Group I averaged 15%
of genome gained and 14% lost; Group II averaged 16% gained and 11%
lost.
[0105] To test the reproducibility of this new CGH method, one
tumor DNA sample was submitted and analyzed twice in a blinded
fashion. Using the t-statistic method, regions of loss and gain
were determined independently on these two specimens. DNA from this
particular tumor (#50) showed a large number of alterations, with
26% of the genome showing a significant gain and 21% of the genome
showing a significant loss. In comparing the results of the two
independent analyses, 89% of the 1247 data channels indicated
identical locations for gains, losses or no change. The primary
differences in the two data sets are at the termini of alterations,
where t values are changing rapidly with channel number. An
illustration of this comparison is shown in FIG. 3, where the t
values in the data channels for chromosome 10 from each of the two
runs are plotted, and the t-thresholds are indicated. In this
illustration both the relative agreements and disagreements can be
viewed. The two data sets agree in 84% of the data channels (46/55)
with the majority of the differences occurring in small regions
(one or two contiguous channels). This duplicate determination
illustrates the power of CGH to present reproducible locations of
gains and losses over the entire genome and also displays its
weakness as a lack of high resolution in defining the location of
alterations.
[0106] CGH Concordance with Allelotyping. To validate this
quantitative statistical approach to CGH analysis, we compared CGH
with allelotyping results on each of the 20 Group I tumor
specimens. FIG. 4 shows an example of the method of comparison for
two tumors on one chromosome.
[0107] Overall, the allelotyping studies resulted in 280
informative results at 49 different loci. A summary of the
comparisons to CGH is shown in Table 2. Of the 280 informative
results obtained with allelotyping, 44 instances could not be
compared to CGH due to imprecise physical mapping of the Southern
probes or microsatellite polymorphisms relative to the termini of
CGH-defined alterations. Of those that could be compared,
discordant results occurred in only 18/236, Twelve of these 18
disagreements occurred in instances where CGH indicated a loss but
the alleles appeared balanced. The level of agreement using the K
statistic (Cohen, J., Educat Psychol Meas, 20:37-46 (1960)), which
takes into account agreement that might occur by chance alone, is K
0.83 (95% confidence interval is 0.70-0.95), with no difference in
the level of agreement of CGH with Southern or microsatellite
analysis.
[0108] Frequency of Regional Chromosomal Alterations: Group I. To
define the general tendencies of DNA alterations in the genome of
untreated tumor metastases, we created a point-by-point histogram
along all chromosome arms showing the region-specific frequency of
losses and gains in this series of 20 untreated prostatic
metastases. FIG. 5 shows the frequency of occurrence of
.vertline.t.vertline.>1.6 for each data channel plotted relative
to an ideogram of each chromosome. It shows that the following 9
chromosomal arms showed loss (in at least one region of each arm)
in more than 40% of the cases: 8p (80%), 13q (75%), 16q (55%), 2q
(50%), 10q (50%), 17p (50%), 5q (45%), 6q (45%) and 15q (45%) and
the following 7 chromosomal arms showed gain (in at least one
region of each arm) in more than 40% of the cases 8q (85%), 1q
(55%), 1p (55%), 2p (50%), 3q (45%), 7q (45%), and 9q (45%) (FIG.
5).
[0109] Close examination of the frequency histograms in FIG. 5
reveals that some of the frequently altered regions contain smaller
sub-regions with higher frequencies of alteration than adjacent
regions. For example, losses on chromosome 13 increase in frequency
continuously from 13q11 to q21.1, remain at about 70% through
13q21. 1-q22 and decrease continuously in frequency from 13q22 to
q35. Thus, the region 13q21.1.q22 displays the highest chance of
containing an important prostate tumor suppressor gene. Detailed
analysis of such regions with a technique of higher resolution
(such as PCR microsatellite allelotyping) is required to define the
region more precisely.
[0110] FIG. 5 shows other chromosomal regions which are altered in
a somewhat lower proportion of Group I tumors. The most frequent of
these are 3p gain (40%), 4p gain (40%) and 11p loss (30%).
Interestingly, there are 12 chromosomal arms where both losses and
gains were detected in at least 20% of the cases. In 7 of these 12
arms the regions of loss and gain do not overlap and it could be
that recessive and dominant oncogenes are distributed throughout
these regions. Again, more precise localization of each region
would address this question better.
[0111] Finally, FIG. 5 shows a modest frequency of alterations
(5-20%) in almost all areas of the genome suggesting that some
clonal chromosomal alterations arise randomly and are maintained in
proliferating prostate cancer cells.
[0112] Frequency of Chromosomal Alterations: Group II. Eleven
specimens from patients with disease progression despite long term
androgen deprivation also were analyzed by CGH. As with Group I
specimens, we performed a point-by-point histogram analysis along
all chromosomal arms showing the region-specific frequency of
alterations. Overall, the results revealed a very similar pattern
of chromosomal alterations as were seen for DNA isolated from Group
I tissues. In particular, the most commonly detected changes were a
loss in chromosome 8p, a gain in chromosome 8q, and a loss in
chromosome 13q. Histograms obtained for these chromosomes of Group
II samples (FIG. 6) appear quite similar to those obtained for
Group I (FIG. 5). In order to test for differences in chromosomal
alterations between Group I and Group II specimens, we constructed
2.times.3 contingency tables at each of the 1247 data channels
along the genome. Each table contained the number of specimens from
each of the two groups that had either a loss, a gain, or no change
at each data channel. We then tested whether there (was a
difference in the frequency of gains or losses for each table using
Fisher's exact test. The result of these analyses showed no more
than the expected number of significant differences (at p<0.05)
based on performing a large number (1247) of tests.
[0113] FIG. 7 shows a summary of the frequency of gains and losses
in regions of the genome which show alterations in many of the
samples. None of the differences between the two groups is
statistically significant (p>0.1). One may conclude from these
data that most chromosomal alterations occur without androgen
deprivation therapy.
[0114] Groups I and II Combined. Since the data sets for the two
groups of tumors were not significantly different, we combined them
and calculated the overall frequency of gain and loss at each
channel (FIG. 7). For other subgroup comparisons of chromosomal
alteration frequency, the combined data set was divided into groups
based on younger or older patient age, higher or lower serum PSA,
and ethnic group (African American vs. Caucasian). Similar
contingency table analyses were carried out as described above. No
regional differences in the frequency of gains or losses were
detected among the groups defined by patient age or serum PSA.
[0115] In contrast, we did find an indication of increased
frequency of gains in the region of 4q25-q28 in African Americans.
With a careful comparison of frequency histograms (such as those
displayed in FIGS. 5 and 6) this region was the only one in which
all 5 blacks showed an alteration. We found that the entire band
4q27 showed a significant gain in samples from 5/5 African
Americans as compared to 3/26 Caucasians. In addition, a larger
region of 6 contiguous data channels in 4q27q28 showed gain in at
least 4/5 samples from African Americans as compared to fewer than
4/26 samples from Caucasians (Fisher's exact p<0.01 for each
comparison). We determined the statistical significance of this
finding by randomly selecting subsets of 5 tumors, from among the
total of 31, and repeating the contingency table analyses for the
entire genome, each time comparing the subset of randomly selected
5 with the remaining 26. We found that only 5% of these samples
contained a section of 6 contiguous data channels with Fisher's
exact p<0.0l (based on 1000 randomly formed subsets). We also
found that only 0.5% of theses randomly generated subsets showed
"significant" gains on chromosome 4. In the comparison of African
Americans to Caucasians, no other regions in the genome differed
significantly, although statistical power is low due to the small
number of blacks in this study.
1TABLE 1 Clinical data an patients from whom tissue was taken for
analysis. Abbreviations: PSA: prostate specific antigen; c:
Caucasian; a: African-American; LN: pelvic lymph node; met:
metastasis; bx: biopsy; TURP: transurethral resection of prostate.
Primary Tumor Estimated Specimen Serum Gleason Tissue Tumor Cell
Number Age Race PSA Score Studied Fraction Group I 50 69 c 21. 7 LN
met 0.9 133 70 c 69.7 9 LN met 0.85 142 61 c 26.2 9 LN met 0.95 170
57 c 3.3 4 LN met 0.9 259 69 c 32 3 7 LN met 0.95 273 53 c 29. 7 LN
met 0.85 275 66 c 123. 6 LN met 0.65 344 60 c 29 7 7 LN met 0.85
375 54 c 12 9 bone met.sup.2 0.75 391 57 c 16.9 5 bone met 0.95 399
65 c 23.6 7 LN met 0.9 402 56 c 41 3 7 LN met 0.9 418 68 a 21.4 8
LN met 0.7 419 57 a 102. 5 LN met 0.95 491 72 a 250. 8 LN met 0.75
497 45 c 130. 8 LN met 0.65 522 57 c 13.3 7 LN met 0.9 556 66 c 9.2
8 LN met 0.85 628 44 a 235. 7 LN met 0.85 635 65 a 31. 6 LN met 0.9
Group II.sup.b 1 75 c 299. 7 prostate bx unknown.sup.c 2 96 c 142.
7 TURP 0.65 3 65 c 1632. 9 prostate bx 0.5 4 67 c 14.9 7 prostate
bx 0.5 5 75 c 209. 9 TURP 0.9 6 85 c 105. 9 TURP 0.8 7 58 c 58.8 6
prostate bx 0.5 8 78 c 22. 7 prostate bx 0.6 9 78 c 232. 7 prostate
bx 0.4 10 74 c 106. 6 skin met 0.7 11 43 c 173. 10 TURP 0.95
.sup.aPatient received one month or androgen deprivation therapy
prior to tissue sampling .sup.bGroup II tumors progressed
clinically while on androgen deprivation therapy. For these tumors,
histological analysis was performed on adjacent surgical samples.
.sup.cSlides could not be located.
[0116]
2TABLE 2 Correlation of CGH findings with allelotyping results.
Results from the two techniques were compared at each informative
southern or microsatellite locus Allelotype Result
(Southern/Microsatellite) CGH Result imbalance balance total loss
or gains* 68 12 80 no alteration 6 150 156 totals 74 162 236 a-In 3
of 4 instances of allelic imbalance on chromosome 8q, southern
analysis was able to detect a gain rather than a loss; by CGH, all
alterations on chromosome 8q were gains. All other allelic
imbalances were losses by CGH. Applying the K statistic (30); K =
0.83 (0.70-0.95 is 95% confidence interval).
[0117] Discussion
[0118] The goal of this study was to gain a pan-genomic view of the
locations and frequencies of regional chromosomal alterations in
prostate cancer. Genetic events leading to the initiation of
prostate cancer are of obvious importance, but since the majority
of prostate cancers never metastasize (Dhom, G., J Cancer Res Clin
Onc, 106:210-18 (1983)), additional genetic events must be involved
in the progression to lethal metastatic prostate cancer. By their
proven ability to metastasize and their relative purity, the tumors
studied here provided excellent material in which to define genetic
alterations potentially involved in both initiation and progression
of prostate cancer. Application of a new method for interpretation
of fluorescence intensity values has led to a standardized CGH
analysis, allowing detection and mapping of these genetic
alterations based on statistical comparisons of intensity ratios
relative to control experiments.
[0119] In 20 of the 31 cases studied, CGH analysis was corroborated
with parallel Southern and microsatellite analysis of allelic
imbalance on the same DNA. The good agreement between these two
analytical techniques (K=0.83) provides assurance that the new,
standardized CGH analysis is demonstrating high sensitivity and
specificity.
[0120] Overall Genomic Considerations. The frequency of copy number
alterations found in DNA samples from prostate cancer tissue
studied here seems rather large when viewed in light of flow
cytometry and other ploidy studies, which have shown that
metastatic prostate cancers are diploid in nearly 50% of the cases
(Stephenson, et al., Cancer Res, 47:2504-7 (1987)). However, the
data presented here suggest that equal proportions of relatively
small regions of the genome are often lost or gained in many tumors
resulting in an overall balance of genetic material and normal
ploidy determination. In addition, when tumors are tetraploid,
changes in copy number among different regions of the genome will
be small relative to the total cellular DNA content. For example,
tumor 399 was determined to be tetraploid on Feulgen staining and
image analysis (data not shown). Thus the losses and gains detected
by CGH must be interpreted from a baseline of 4 allelic copies.
Losses and gains were detected in approximately 5% of and 18%,
respectively, of the 1247 data channels across the genome. Although
we were unable to determine exactly how many copies were lost or
gained for each of the individual alterations, the data support the
view that metastatic prostate cancers do contain critical DNA
alterations which may be not be detectable when measuring gross DNA
content. Since ploidy has been reported to be of independent
prognostic value in some prostate cancer studies (Shankey, et al.,
Cytometry, 14:497-500 (1993)), we would suggest that ploidy
measurements plus CGH or allelotyping analysis could provide
improved tumor-specific prognostic information.
[0121] The results provided here indicate that most regions of the
genome are altered in at least 5 percent of advanced prostate
cancer cases. These seemingly random alterations would not have
been detected had they not been clonally present in a significant
number of cells in the tissues from which DNA was extracted. We
presume that chromosomal regions with low frequency of alteration
occur as a result of random genetic instability of advanced cancer,
and they probably do not contain genes important to the aggressive
phenotype.
[0122] In the present study gains were present as often as losses.
However, the gains detected here were relatively low level in
red/green fluorescence ratio and generally involved large regions
or whole chromosome arms. No short, high level amplifications
suggestive of single oncogene amplification were found such as
those described for breast cancer (Kallioniemi, et al., Proc Natl
Acad Sci USA, 91:2156-60 (1994)). Our results indicate a more
subtle shift in gene copy numbers which correlates with earlier
reports on relatively low levels of amplification in prostate
cancer (Visakorpi, et al., Nature Genetics, 9:401-6 (1995); Bova,
et al., Cancer Res, 53:3869-73 (1993); Van Den Berg, et al., Clin
Ca Res, 1:11-18 (1993); Brothman, et al., Cancer Res, 50:3795-803
(1990)).
[0123] The above examples are provided to illustrate the invention
but not to limit its scope. Other variants of the invention will be
readily apparent to one of ordinary skill in the art and are
encompassed by the appended claims. All publications, patents, and
patent applications cited herein are hereby incorporated by
reference for all purposes.
* * * * *